We liken our multifarious activities to the playing massive symphony orchestra. Spearheading, conducting, welding the baton is our Chairman, Dr. Gopal Munjal; sticking to the well transcribed score, aware of the cadences, pauses, tumbles and percussion, improving every day to create a masterpiece that speaks of titanic strength, and an internal unity of purpose.
Each member of Ind-Swift is a player in that symphonic poem. A perfect coordination leading to a flawless and rapturous rendition and performance. This supportive teamwork, our highest quality of produce and dedication to our task has taken Ind-Swift group to INR 375 Crores in 2003-04. Today we are poised for a proper lebensraum. Poised to reach INR 1000 crores in year 2007 as envisaged by us.
Incorporated in 1986, Ind-Swift Limited is the flagship company of India based Ind-Swift Group. Ind-Swift has emerged as a key contender in the domestic pharmaceutical market. To meet ever-growing market demands, the company continuously updated and modernized its manufacturing facilities, and weathered stiff competition to cement its place in the competitive Indian market.
At present, Ind-Swift’s multipurpose; multilocational manufacturing set-up is spread across the north Indian states. The company has facilities to manufacture various dosage forms including oral solutions and suspensions, dry syrups and hard gelatin capsules (General and Beta-lactam), tablets (general, coated, sustained release and effervescent forms), dermatologicals comprising of creams, ointments and gels, eye and ear drops and injectables (Ampoules and vials).
We enjoy contemporary,
Manufacturing Facilities which are in line with the highest international regulatory standards. The Company has geared up its activities towards formulation (finished dosage forms) exports, both in regulated as well as non-regulated markets. In the first phase, non-regulated markets were selected. Product registration process is already complete for CIS, SAARC, Middle East and South East Asian countries.
To capitalize on the future opportunities, the company has set up a manufacturing facility [comprising of all the sections], conforming to US FDA, MCA TGA standards. This facility will be utilised for contract as well as company's own manufacturing, for the purpose of exports to regulated markets. The existing manufacturing facilities as per WHO GMP standards will take care of the domestic market needs.
Today we command the
Research and Development spawning facilities offered by our State of Art drug formulations, chemical research and analytical development center; equipped with the latest equipments needed for combinational synthesis, ultramodern HPLC & GC systems etc. Our facility is recognized by the ministry of Science and Technology, Government of India.
A well knit team committed, enthused and brilliant scientists drawn from different streams, pursuing interesting, commercially alluring pharmaceutical leads for Ind swift. A comprehensive and flexible pilot plant is there to translate our hunches and insights into money spinners.
We are high on researching such AYURVEDIC medicinal plants which show a promise in treating chronic ailments and life style disorders.
All these developments have allowed us to successfully market our finished formulations, generics in incremental amounts, both nationally and internationally.
The company markets formulations, through its different divisions, focusing on the needs of various therapeutic segments, which include Cardiology, Diabetology, Pediatrics, Gynecology, Surgery, Orthopedics, Ophthalmology, Neuropsychiatry, Anesthesiology. Formulations (finished dosage forms) are marketed through Ethical Division, Super Speciality Division, Mukur Division, Resurgence Division, Health Care Division, Max Care Division and Bio sciences Division. A talented team of research scientists, formulation experts, clinical development and regulatory affairs professionals support the Company's marketing efforts across the country.